[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Pancreatic cancer Global Clinical Trials Review, H2, 2019

July 2019 | 2082 pages | ID: PC36A1D0E706EN
GlobalData

US$ 2,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Pancreatic cancer Global Clinical Trials Review, H2, 2019

SUMMARY

GlobalData's clinical trial report, “Pancreatic cancer Global Clinical Trials Review, H2, 2019' provides an overview of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) clinical trials scenario. This report provides top line data relating to the clinical trials on End-Stage Kidney Disease (End-Stage Renal Disease or ESRD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

REASONS TO BUY
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Pancreatic Cancer to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Pancreatic Cancer to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Pancreatic Cancer Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Pancreatic Cancer
Jul 03, 2019: Cantargia announce full recruitment of CAN04 monotherapy arm in ongoing phase IIa clinical trial
Jul 03, 2019: Immune-boosting compound makes immunotherapy effective against pancreatic cancer
Jun 24, 2019: NOXXON announces leading international pharma to evaluate NOX-A12 in new indication
Jun 19, 2019: UA researcher studying new treatment to prolong survival in advanced biliary tract cancers
Jun 13, 2019: Mereo BioPharma Group: Update on Etigilimab (TIGIT) partnership
Jun 03, 2019: BERG presents on ubidecarenone at The 2019 ASCO Annual Meeting
Jun 02, 2019: Corvus Pharmaceuticals presents initial CPI-006 phase 1/1b clinical data at 2019 ASCO Annual Meeting
Jun 02, 2019: Cantargia: Presentation of Phase I clinical data on antibody CAN04 at ASCO
Clinical Trial Profile Snapshots
Appendix 2152
Abbreviations 2152
Definitions 2152
Research Methodology 2153
Secondary Research 2153
About GlobalData 2154
Contact Us 2154
Disclaimer 2154
Source 2155

LIST OF TABLES

Pancreatic Cancer Therapeutics, Global, Clinical Trials by Region, 2019*
Pancreatic Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, North America, Top Countries, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019*
Proportion of Pancreatic Cancer to Oncology Clinical Trials, G7 Countries (%), 2019*
Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
Proportion of Pancreatic Cancer to Oncology Clinical Trials, E7 Countries (%), 2019*
Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
Pancreatic Cancer Therapeutics, Global, Clinical Trials by Phase, 2019*
Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2019*
Pancreatic Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
Pancreatic Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*

LIST OF FIGURES

Pancreatic Cancer Therapeutics, Global, Clinical Trials by Region (%), 2019*
Pancreatic Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019*
Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019*
Pancreatic Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019*
Proportion of Pancreatic Cancer to Oncology Clinical Trials, G7 Countries (%), 2019*
Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2019*
Pancreatic Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019*
Proportion of Pancreatic Cancer to Oncology Clinical Trials, E7 Countries (%), 2019*
Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2019*
Pancreatic Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019*
Pancreatic Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2019*
Pancreatic Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2019*
Pancreatic Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
Pancreatic Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019*
Pancreatic Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019*
GlobalData Methodology 2153

COMPANIES MENTIONED

F. Hoffmann-La Roche Ltd
Novartis AG
Pfizer Inc
Celgene Corp
AstraZeneca Plc
Eli Lilly and Co
Sanofi
Merck & Co Inc
Bristol-Myers Squibb Co
Otsuka Holdings Co Ltd


More Publications